Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBTC Study 31 PK/PD Substudy
NCT02563327Phase 3Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Jan 2016
- Primary completion
- Aug 2021
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 3 trial of rifapentine, moxifloxacin in Tuberculosis (TB), sponsored by Centers for Disease Control and Prevention. Started Jan 2016; status: completed.
02
Drugs
rifapentinemoxifloxacin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02563327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02563327.